‹ Back to the alert

Prints on one A4 page for most notices. Long batch lists carry on to a second page, with the column headings repeated.

Defect notification check

Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/5mL, EL(26)A/46

Class 4 defect notification — Caution in use. Usually minor defects in packaging or other printed materials.

Reference
EL(26)A/46
Issued
5 Nov 2026
Marketing authorisation holder
Sandoz Limited

Scan for the official GOV.UK notice, or search GOV.UK for EL(26)A/46.

Pharmshark is not an official alerting route. Make sure your pharmacy receives alerts directly from the MHRA and through your organisation, and always act on the official GOV.UK notice. Printed from pharmshark.com on 21 November 2026; the notice may have changed since, so scan the QR code to check. Source: the MHRA on GOV.UK. Contains public sector information licensed under the Open Government Licence v3.0. Pharmshark is not affiliated with or endorsed by the MHRA.

Pharmacy
Notice received (date)
Date checked
Checked by
Returns / credit reference (if any)
Batches in the GOV.UK notice (number)
Copied in and checked by

No affected stock found, after checking every batch from the GOV.UK notice

Copy the batch numbers from the GOV.UK notice. Pharmshark could not list them safely from this notice, so the rows below are blank.

What the notice says about its batches:

Co-Amoxiclav powder for oral suspension 250/62.5 mg/5mL: All batches are currently impacted.
Write in every batch from the GOV.UK notice
ProductBatch numberExpiry Packs foundAction takenInitials

What needs to be done

  • Pharmacists: do not use the Sandoz Summary of Product Characteristics (SmPC) dosing table for weight-adjusted dosing of this medicine.
  • Use the corrected dosing information from Annex 1 instead.
  • Be aware that all batches are currently impacted, but the notice says the quality of the powder for oral suspension is not affected.
  • If you are asked about side effects or possible overdose, the notice says suspected adverse reactions should be reported via the MHRA Yellow Card scheme.
  • Read and act on the official GOV.UK notice.

Pharmshark summary, checked by Chris Dotchin. It is not the official notice: always read and act on the GOV.UK notice.